BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Callisto Pharmaceuticals 

420 Lexington Avenue, Suite 1609

New York  New York  10170  U.S.A.
Phone: 212-297-0010 Fax: 212-297-0020


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology

Segment
Pharmaceuticals





 Company News
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals 1/18/2013 9:16:36 AM    More...
Callisto Pharmaceuticals Stockholders Approve Merger With Synergy Pharmaceuticals 1/15/2013 9:19:08 AM    More...
Synergy Pharmaceuticals Signs Definitive Agreement to Acquire Callisto Pharmaceuticals 7/23/2012 9:50:56 AM    More...
Callisto Pharmaceuticals Adjourns Annual Stockholders Meeting Due to Lack of a Quorum 7/12/2010 9:32:21 AM    More...
Callisto Pharmaceuticals Redirects Atiprimod Clinical Development to Treat Rheumatoid Arthritis 1/27/2009 9:52:31 AM    More...
Callisto Pharmaceuticals’ Majority-Owned Subsidiary Synergy Pharmaceuticals Completes Phase I Trial of SP-304 in Volunteers 12/9/2008 1:23:38 PM    More...
Callisto Pharmaceuticals Announces $3.0 Million Financing by Its Synergy Pharmaceuticals Subsidiary and Related Transactions Leaving Callisto with a 68% Stake in Synergy 7/21/2008 11:08:20 AM    More...
Callisto Pharmaceuticals Opens Phase I Clinical Trial of SP-304 to Treat Chronic Constipation and Irritable Bowel Syndrome 6/4/2008 10:12:57 AM    More...
Callisto Pharmaceuticals Reports Promising Interim Phase II Data for Atiprimod in Advanced Carcinoid Cancer 5/16/2008 8:57:28 AM    More...
Callisto Pharmaceuticals Receives Notice of Delisting From AMEX - Subject to Appeal 4/14/2008 9:26:24 AM    More...
12345678910...